BRISTOL-MYERS SQUIBB'S WOUND CARE, OSTOMY PRODUCT REVENUES ADVANCE IN THIRD QUARTER; BIOMATRIX' SYNVSIC APPROVAL PROMPTS $12 MIL. WYETH-AYERST PAYMENT
This article was originally published in The Gray Sheet
Executive Summary
Sales of wound-care products increased 12% in the third quarter of 1997 to $57 mil., making that category the top gaining segment of Bristol-Myers Squibb's medical device group.